Last reviewed · How we verify
Duobrii®
Duobrii is a fixed-dose combination of halobetasol propionate (a potent topical corticosteroid) and tazarotene (a retinoid) that reduces inflammation and normalizes skin cell differentiation in psoriasis.
Duobrii is a fixed-dose combination of halobetasol propionate (a potent topical corticosteroid) and tazarotene (a retinoid) that reduces inflammation and normalizes skin cell differentiation in psoriasis. Used for Plaque psoriasis.
At a glance
| Generic name | Duobrii® |
|---|---|
| Also known as | Halobetasol propionate 0.01%/tazarotene 0.045% lotion, HP/TAZ, halobetasol propionate and tazarotene |
| Sponsor | Icahn School of Medicine at Mount Sinai |
| Drug class | Topical corticosteroid and retinoid combination |
| Target | Glucocorticoid receptor (halobetasol); retinoic acid receptors (tazarotene) |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
Halobetasol propionate works as a Class I (super-potent) topical corticosteroid by binding glucocorticoid receptors to suppress inflammatory cytokines and immune cell infiltration. Tazarotene is a third-generation retinoid that binds retinoic acid receptors to promote keratinocyte differentiation and reduce hyperproliferation. The combination provides synergistic anti-inflammatory and anti-proliferative effects.
Approved indications
- Plaque psoriasis
Common side effects
- Application site irritation
- Application site burning
- Skin atrophy
- Teratogenicity risk (retinoid component)
Key clinical trials
- Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults (PHASE3)
- Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis (PHASE4)
- A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis. (EARLY_PHASE1)
- Safety and Efficacy of IDP-118 Lotion to Ultravate® in the Treatment of Plaque Psoriasis (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Duobrii® CI brief — competitive landscape report
- Duobrii® updates RSS · CI watch RSS
- Icahn School of Medicine at Mount Sinai portfolio CI